Combination treatment for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are able to take care of yourself and do light daily activities (ECOG score 0 or 1).
- Your doctor has confirmed that your small cell lung cancer is extensive-stage (has spread beyond one lung).
- You have not had any chemotherapy or radiation for extensive-stage small cell lung cancer before this study.
- You have not had radiation to your chest in the past, and you are not planning to have it during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
This trial tests a new combination of immunotherapy (adebrelimab), a targeted drug (famitinib), and standard chemotherapy for people with extensive stage small cell lung cancer who have not had treatment before. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation therapy to see if it works better than standard treatment for people with extensive-stage small cell lung cancer who have not been treated before.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.
This trial is testing a new approach for extensive-stage small cell lung cancer (SCLC) that has not been treated before. It combines a high-dose chemotherapy regimen with a drug called adebrelimab (an immunotherapy) and a stem cell transplant to help your body recover. The goal is to see if this powerful combination can work better than standard treatment.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.